



Small Animal Patients Needed for Clinical Studies – March 2024

The following clinical studies are recruiting patients at UW Veterinary Care. For more information, please visit our [Website](#) or contact [Amy Elbe](#), CVT, LAT, Clinical Research Technician, at **608-890-3484**. Thank you for helping improve the health of animals.

- **Cardiology**
 - Participant in the Dog Aging Project Trial of Rapamycin in Aging Dogs (TRIAD) Study
- **General Surgery**
 - Dogs undergoing surgery for **Laryngeal Paralysis** – evaluate EMG and stimulation responsiveness
- **Genetics – investigating genetic heritability**
 - **Cats over 10 years with NO history of Feline Oral Resorptive Lesions**
 - **Newfoundlands & Labrador Retrievers** with non-contact **Cranial Cruciate Rupture**. Newfoundlands 5 years and older without a history of cruciate disease.
 - Dogs (any breed) 8 years or older with **Laryngeal Paralysis**.
- **Internal Medicine**
 - **Dogs with Blastomycosis** – evaluation of relationship between urine concentration and Blastomyces antigen level.
 - **Cats with AKI/pyelonephritis** – investigation of serum amyloid A as an inflammatory marker to guide treatment
 - **Dogs with newly diagnosed ITP** - investigation of changes in cytokines during treatment
 - **Dogs with Stage II, III, and IV chronic kidney disease** – investigate if Doxycycline or Clavamox are passed in the urine in dogs with kidney disease in the same concentrations as dogs without kidney disease.
 - Cats with **FIP** (feline infectious peritonitis) ***Phase 2** – investigate the efficacy of in-hospital treatment of FIP.
- **Neurology**
 - **Dogs with Meningoencephalitis of Unknown Etiology (MUE)** – evaluate 2 treatment medication protocols
 - **Cats 12 years and older being euthanized** - investigate neurologic, ophthalmic, and behavioral changes
- **Oncology**
 - ***NEW - Cats with Large Cell Lymphoma** – Determine the maximum tolerated dose, tolerability, and adverse event profile of Pevonedistat
 - **Dogs with solid tumors (except oral malignant melanoma, mast cell tumor, histiocytic sarcoma) without metastasis** - evaluate shingrix/ gardasil vaccine repurposed for immunity
 - **Dogs with Oral Melanoma, stage III** – Evaluate new medication
 - **Dogs with Malignant Melanoma** (except malignant melanoma on the lip only) – Evaluate new medication
 - **Dogs with primary pulmonary tumors or 1-3 metastatic pulmonary lesions**– Pilot study to evaluate Synchrony technology for tumors that may move during treatment.
 - **Dogs on CHOP for Lymphoma** evaluate Visbiome Probiotic vs Metronidazole for diarrhea
 - **Dogs with diffuse large cell B cell lymphoma** - evaluate the DNA of dogs enrolled through blood testing and lymph node biopsy. These patients must go through traditional CHOP protocol.
 - Dogs with **Metastatic Cancer that has an accessible tumor >2cm (except mast cell tumor & hemangiosarcoma)** – evaluate an intravenous, targeted radiation treatment combined with an immunotherapy treatment
 - Dogs with **Lymphoma or Non-Sarcomatous Solid tumors** – evaluate the effectiveness and tolerability of 2 new anti-cancer agents.
 - **Dogs with Lymphoma** – investigate effectiveness of Verdinexor compared to a placebo
- **Ophthalmology**
 - **Dogs being euthanized for reasons other than eye disease** – look at post-mortem changes
 - **Dogs diagnosed with SARDS** – evaluate clotting system in dogs with SARDS to see if related to vision loss
 - **Cairn Terriers** of any age with **Ocular Melanosis** or Cairn Terriers over 12 yrs without ocular melanosis.
 - **Huskies/Entlebucher Mt Dogs** 10+ years old or with a history of glaucoma – investigate genetic basis of glaucoma